1 Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma:a retrospective study Hilmi Ege, Morie A.Gertz,

Slides:



Advertisements
Similar presentations
Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.
Advertisements

Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ Multiple Myeloma: Is FISH passé? Scottsdale, Arizona Rochester, Minnesota Jacksonville,
Staff Oncologist, Mayo Clinic Arizona
Casulo C et al. Proc ASH 2013;Abstract 510.
Systemic inflammatory response syndrome score at admission independently predicts mortality and length of stay in trauma patients. by R2 黃信豪.
PROGNOSTIC SIGNIFICANCE OF PRIMARY TUMORAL FDG UPTAKE MEASURED BY PET: Systematic Review and Meta-analysis Ben A. Dwamena, MD.
Objectives To introduce the terminology used in describing the plasma cells neoplasm. To explain the physiology of the normal cells & the pathological.
The All Breast Cancer Report was published in October breastscreen/research.html#breast- cancer-report.
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.
10 Minutes Talk 吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
A Retrospective Study of Outcomes in Pediatric Hematology/Oncology Patients Receiving Continuous Venovenous Hemodialysis Y Avent 1, N Henderson 1, T Collie.
WEILL.CORNELL.EDU Should All Eligible Patients with Mantle Cell Lymphoma Be Transplanted? Answer: No Peter Martin, M.D. The Charles, Lillian and Betty.
High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide 1 Cereblon Expression Predicts.
Multiple Myeloma Definition:
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria MULTIPLE MYELOMA.
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,
Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney Sophina Hissaund FY2.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE CD49d and CD26 are independent prognostic markers for disease progression in patients.
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:
CAT 4: How to Read a Prognosis Article Maribeth Chitkara, MD Rachel Boykan, MD.
Continued Overall Survival Benefit After 5 Years’ Follow-Up with Bortezomib-Melphalan-Prednisone (VMP) versus Melphalan-Prednisone (MP) in Patients with.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Results Abstract Analysis of Prognostic Web-based Models for Stage II and III Colon Cancer: A Population-based Validation of Numeracy and Adjuvant! Online.
Hierarchical Cluster analysis of Florescent in Situ Hybridisation in newly diagnosed myeloma patients Ieuan Walker BSc. (hons) MSc
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia? Eur J Haematol Feb. R2 이 홍 주.
R2 김재민 / Prof. 윤휘중 Journal conference 1.
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
R4 Jae Joon Han.
P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.
Impaired RV Global Longitudinal Strain Is Associated With Poor Long-Term Clinical Outcomes in Patients With Acute Inferior STEMI Journal of the American.
Biomarkers for personalized therapy in myeloma
R1.이용석 / modulator pf.한재준.
Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12
Palumbo A et al. Proc ASH 2012;Abstract 200.
Prognostic Implications of Neutrophil to Lymphocyte Ratio in the Treatment of Metastatic Renal Cell Carcinoma with Pazopanib and Sunitinib Ajay Raghunath1,
Immunoscore Prognostic in Colon Cancer
TBCRC (the translational breast cancer research consortium) 005 Prospective study
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Patient Characteristic
Peripheral T-Cell Lymphoma in 2013
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Multiple Myeloma: Diagnosis and Treatment
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.
Palumbo A et al. Proc ASCO 2011;Abstract 8007.
Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma  Egil S. Blix, Anders.
Multiple Myeloma Overview all transplants, autologous and allogeneic (period ) N=28.887
Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma  Egil S. Blix, Anders.
Presented at EHA2018 Michael Austin
Alcoholic liver disease in intensive care
Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional.
Managing Your Patient’s Maintenance Therapy for Multiple Myeloma
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study  Luis F.
Kantarjian HM et al. Blood 2008;112:Abstract 635.
Minimal Residual Disease in Multiple Myeloma
Presentation transcript:

1 Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma:a retrospective study Hilmi Ege, Morie A.Gertz, Svetomir N.Markovic Div. of Hematology/Dep.of medicine Mayo Clinic College of Medicine, MN, USA British journal of Haematology,vol 141,June 2008

2 Introduction  Absolute lymphocyte count(ALC) recovery after autologous stem cell transplantation - prognostic factor for survival in multiple haematological malignancies  Quantitative numbers of CD 19+ cells at the time of MM diagnosis - survival  Failed to compare the prognostic ability of CD 19+ cell against chromosome analysis and ISS  ALC at diagnosis was analyed in newly diagnosed MM to assess whether ALC, marker of host immune status, is associated with survival at diagnosis of MM

3 Patients and methods  Patient population 1835 Multiple myeloma patients at the Mayo Clinic,1994~2002,originally diagnosed,followed and treated at the Mayo Clinic ->537 MM Pts. Excluded- concomitant malignant diagnosis,other plasma proliferative disorder,amyloidosis  End point Primary end point - to assess the impact on overall survival (OS) based on ALC at diagnosis in newly diagnosed MM Pts Secondary end point - whether the ALC at diagnosis was an independent prognostic factor for OS in MM Pts  Prognostic factors ISS,age,albumin ( 3.5mg/l),BM plasma cell(BMPC>40%),circulating plasma cells,LDH,plsama cell labelling index

4 Results

5

6

7

8

9

10 Discussion  First report linking ALC at diagnosis to prognosis newly diagnosed MM – strong independent predictor of treatment outcome in MM Pts  Previous studies – quantitative numbers of CD19 or development of T cell clones associated survival but failed to analysis against cytogenetics or ISS  Human studies – T cell has suppressive effect on immunoglobulin production, lymphocyte has antimyeloma activity ->host immune system to MM

11 Limitations  First - none of the Pts had their lymphocyte subset analysed at diagnosis  Second - 57% of cohort has chromosomes studies performed by conventional cytogenetics,false negative results so conventional karyotyping was not included  Third - Choice of standard Tx versus ASCT biased by physicians’s preferance based on Pt’s characteristics but higher ALC better OS regardless of their Tx

12 Conclusion  In newly diagnosed MM, ALC is independent prognostic factor for OS, suggesting significant role of host immune status in survival of MM